Scholarlink

Background <p>Recent infectious disease outbreaks, notably COVID-19, have significantly affected society. Despite initial preventive measures and vaccination efforts, COVID-19 persist, requiring effective treatments. Commonly used corticosteroids face debate over their efficacy, with studies questioning their impact on COVID-19 outcomes and their association with hyperglycemia, particularly in diabetic patients. This complex interaction between COVID-19, diabetes, and corticosteroid use underscores the need for alternative treatments like pentoxifylline (PTXF) to manage inflammation and mitigate corticosteroid-induced hyperglycemia in diabetic patients.</p> Method <p>This study aimed to assess the effectiveness of PTXF in diabetic COVID-19 patients through a randomized, controlled trial. Patients with specific criteria were recruited from two academic hospitals in Yazd, Iran and randomized to receive PTXF or dexamethasone along with other medications. Outcome measures included inflammatory markers, clinical symptoms, adverse events, and hyperglycemic-related risks.</p> Result <p>The clinical trial, involving 47 diabetic patients, revealed that on the seventh day, the PTXF group exhibited lower mean levels of WBC, neutrophil, lymphocyte, IL6, and CRP compared to the dexamethasone group (<i>p</i>-value &lt; 0.05). In addition, the rise in blood sugar during the illness was significantly lower in the PTXF group due to great importance and interest.</p> Conclusions <p>PTXF may present promising evidence in improving COVID-19 patients by reducing inflammatory parameters, especially in diabetic patients.</p> <p><i>Trial Registration</i>: Trial registry date: 2024-10-12, Trial Registry number: IRCT20190810044500N29</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring pentoxifylline as an alternative treatment for dexamethasone in diabetic patients with COVID-19: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Mohsen Gholinataj Jelodar,
  • Farahnaz Hoseinzadeh,
  • Samaneh Mirzaei,
  • Zahra Falahati,
  • Fatemeh Saghafi

摘要

Background

Recent infectious disease outbreaks, notably COVID-19, have significantly affected society. Despite initial preventive measures and vaccination efforts, COVID-19 persist, requiring effective treatments. Commonly used corticosteroids face debate over their efficacy, with studies questioning their impact on COVID-19 outcomes and their association with hyperglycemia, particularly in diabetic patients. This complex interaction between COVID-19, diabetes, and corticosteroid use underscores the need for alternative treatments like pentoxifylline (PTXF) to manage inflammation and mitigate corticosteroid-induced hyperglycemia in diabetic patients.

Method

This study aimed to assess the effectiveness of PTXF in diabetic COVID-19 patients through a randomized, controlled trial. Patients with specific criteria were recruited from two academic hospitals in Yazd, Iran and randomized to receive PTXF or dexamethasone along with other medications. Outcome measures included inflammatory markers, clinical symptoms, adverse events, and hyperglycemic-related risks.

Result

The clinical trial, involving 47 diabetic patients, revealed that on the seventh day, the PTXF group exhibited lower mean levels of WBC, neutrophil, lymphocyte, IL6, and CRP compared to the dexamethasone group (p-value < 0.05). In addition, the rise in blood sugar during the illness was significantly lower in the PTXF group due to great importance and interest.

Conclusions

PTXF may present promising evidence in improving COVID-19 patients by reducing inflammatory parameters, especially in diabetic patients.

Trial Registration: Trial registry date: 2024-10-12, Trial Registry number: IRCT20190810044500N29